Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher framingham and VACS risk index scores

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Mooney, Sarah ^a   Tracy, Russell ^a   Osler, Turner ^a   Grace, Christopher ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD4 ANTIGEN; CHOLESTEROL; CREATININE; CYSTATIN C; D DIMER; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FIBROSIS; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIXED INFECTION; OBESITY; PREDICTION; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VETERANS AGING COHORT STUDY SCORE; VIRUS INHIBITION; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; PROCEDURES; RISK FACTOR; VERMONT; VETERAN; VIROLOGY;

ADULT; BIOMARKERS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; VERMONT; VETERANS;

EID: 84955456603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144312     Document Type: Article

References (33)

1. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Home FM, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008 Aug 15; 47(4):542-53. doi: 10.1086/590150
2. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the Gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013 Dec 18; 8(12):e81355. doi: 10.1371/journal.pone.0081355
3. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr. 2003 Aug 1; 33(4):506-512.
4. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infetced patients: The French national Mortalité 2005 study. J Hepatol. 2009 Apr; 50(4):736-45. doi: 10.1016/j.jhep.2008.11.018
5. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected individuals versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008 Sep; 93(9):3499-504. doi: 10.1210/jc.2008-0828
6. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011 May 4; 103(9):753-62. doi: 10.1093/jnci/djr076
7. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007 Nov; 62(11):1279-86.
8. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011 Dec; 53 (11):1120-6. doi: 10.1093/cid/cir627
9. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013 Oct 17; 39(4):633-45. doi: 10.1016/j.immuni.2013.10.001
10. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21; 5(10):e203. doi: 10. 1371/journal.pmed.0050203
11. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010 Nov; 5 (6):498-503. doi: 10.1097/COH.0b013e32833ed6f4
12. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection. J Infect Dis. 2010 Jun 15; 201 (12):1788-95. doi: 10.1086/652749
13. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, et al. Higher levels of CRP, D-dimer, IL-6 and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011 Jun 1; 203(11):1637-46. doi: 10.1093/infdis/jir134
14. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, et al. Associations of inflammatory markers with AIDS and non-AIDS Clinical events after Initiation of antiretroviral therapy: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014 Feb 1; 65 (2):167-74. doi: 10.1097/01.qai.0000437171.00504.41
15. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012 Apr; 54(7):984-94. doi: 10.1093/cid/cir989
16. Guzmán-Fulgencio M, Medrano J, Rallón N, Echeverria-Urabayen A, Miguel Benito J, Restrepo C, et al. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. J Infect. 2011 Nov; 63(5):382-90. doi: 10.1016/j.jinf.2011.08.006
17. Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, et al. Towards a combined prognostic index for survival in HIV infection: The role of 'non-HIV' biomarkers. HIV Med. 2010 Feb; 11 (2):143-51. doi: 10.1111/j.1468-1293.2009.00757.x
18. Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: A North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013 Feb 1; 62(2):149-63. doi: 10.1097/QAI.0b013e31827df36c
19. D'Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012 Jun; 205 Suppl 3:S362-7. doi: 10.1093/infdis/jis196
20. Framingham Risk Assessment Tool, National Heart Lung and Blood Institute. Available: http://www. cvdrisk.nhlbi.nih.gov.
21. Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, et al. Changes in inflammatory and coagulation biomarkers: A randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011 Jan 1; 56(1):36-43. doi: 10.1097/QAI.0b013e3181f7f61a
22. Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010 Jul 17; 24(11):1657-65. doi: 10.1097/QAD.0b013e3283389dfa
23. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011; 62:141-doi: 10.1146/annurev-med-042909-093756
24. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012 Jul; 55(1):126-36. doi: 10.1093/cid/cis406
25. Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, et al. Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One. 2014 Apr 11; 9(4):e95061. doi: 10.1371/journal.pone.0095061
26. Shirley DK, Kaner RJ, Glesby MJ. Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Clin Infect Dis. 2013 Jul; 57(2):275-82. doi: 10.1093/cid/cit207
27. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008 Nov 30; 22(18):2409-18. doi: 10.1097/QAD.0b013e3283174636
28. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral therapy. N Engl J Med. 2006 Nov 30; 355(22):2283-96.
29. INSIGHT START study group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27; 373(9):795-807. doi: 10.1056/NEJMoa1506816
30. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014 Apr 15; 209(8):1156-64. doi: 10.1093/infdis/jiu012
31. Silver SA, Huang M, Nash MM, Prasad GV. Framingham risk score and novel cardiovascular risk factors underpredict major cardiac events in kidney transplant recipients. Transplantation. 2011 Jul 27; 92 (2):183-9. doi: 10.1097/TP.0b013e31821f303f
32. Chen SC, Su HM, Tsai YC, Huang JC, Chang JM, Hwang SJ, et al. Framingham risk score with cardiovascular events in chronic kidney disease. PLoS One. 2013; 8(3):e60008. doi: 10.1371/journal.pone. 0060008
33. Armah KA, Quinn EK, Cheng DM, Tracy RP, Baker JV, Samet JH, et al. Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: A cross-sectional study. BMC Infect Dis. 2013 Aug 29; 13:399. doi: 10.1186/1471-2334-13-399